These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1076 related articles for article (PubMed ID: 16176994)

  • 1. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset.
    Berglin E; Johansson T; Sundin U; Jidell E; Wadell G; Hallmans G; Rantapää-Dahlqvist S
    Ann Rheum Dis; 2006 Apr; 65(4):453-8. PubMed ID: 16176994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP).
    Forslind K; Ahlmén M; Eberhardt K; Hafström I; Svensson B;
    Ann Rheum Dis; 2004 Sep; 63(9):1090-5. PubMed ID: 15308518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic laboratory markers of joint damage in rheumatoid arthritis.
    Lindqvist E; Eberhardt K; Bendtzen K; Heinegård D; Saxne T
    Ann Rheum Dis; 2005 Feb; 64(2):196-201. PubMed ID: 15458956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis.
    Kaltenhäuser S; Pierer M; Arnold S; Kamprad M; Baerwald C; Häntzschel H; Wagner U
    Rheumatology (Oxford); 2007 Jan; 46(1):100-4. PubMed ID: 16728439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA.
    Agrawal S; Misra R; Aggarwal A
    Clin Rheumatol; 2007 Feb; 26(2):201-4. PubMed ID: 16572283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.
    Rantapää-Dahlqvist S; de Jong BA; Berglin E; Hallmans G; Wadell G; Stenlund H; Sundin U; van Venrooij WJ
    Arthritis Rheum; 2003 Oct; 48(10):2741-9. PubMed ID: 14558078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis.
    Vencovský J; Machácek S; Sedová L; Kafková J; Gatterová J; Pesáková V; Růzicková S
    Ann Rheum Dis; 2003 May; 62(5):427-30. PubMed ID: 12695154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis.
    Berglin E; Padyukov L; Sundin U; Hallmans G; Stenlund H; Van Venrooij WJ; Klareskog L; Dahlqvist SR
    Arthritis Res Ther; 2004; 6(4):R303-8. PubMed ID: 15225365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis.
    Mewar D; Coote A; Moore DJ; Marinou I; Keyworth J; Dickson MC; Montgomery DS; Binks MH; Wilson AG
    Arthritis Res Ther; 2006; 8(4):R128. PubMed ID: 16859535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.
    Syversen SW; Gaarder PI; Goll GL; Ødegård S; Haavardsholm EA; Mowinckel P; van der Heijde D; Landewé R; Kvien TK
    Ann Rheum Dis; 2008 Feb; 67(2):212-7. PubMed ID: 17526555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome.
    Quinn MA; Gough AK; Green MJ; Devlin J; Hensor EM; Greenstein A; Fraser A; Emery P
    Rheumatology (Oxford); 2006 Apr; 45(4):478-80. PubMed ID: 16287917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of HLA-DRB1 shared epitope, -308 tumor necrosis factor-alpha gene promoter polymorphism, rheumatoid factor, anti-citrullinated peptide antibodies, and early erosions for predicting radiological outcome in recent-onset rheumatoid arthritis.
    Reneses S; González-Escribano MF; Fernández-Suárez A; Pestana L; Davila B; Wichmann I; García A
    J Rheumatol; 2009 Jun; 36(6):1143-9. PubMed ID: 19411391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of anticyclic citrullinated peptide antibodies and/or rheumatoid factor status and clinical presentation in early arthritis: results from the ESPOIR cohort.
    Mouterde G; Lukas C; Goupille P; Flipo RM; Rincheval N; Daurès JP; Combe B
    J Rheumatol; 2014 Aug; 41(8):1614-22. PubMed ID: 25028372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating secretory IgA antibodies against cyclic citrullinated peptides in early rheumatoid arthritis associate with inflammatory activity and smoking.
    Roos K; Martinsson K; Ziegelasch M; Sommarin Y; Svärd A; Skogh T; Kastbom A
    Arthritis Res Ther; 2016 May; 18(1):119. PubMed ID: 27215344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.
    Caspi D; Anouk M; Golan I; Paran D; Kaufman I; Wigler I; Levartovsky D; Litinsky I; Elkayam O
    Arthritis Rheum; 2006 Feb; 55(1):53-6. PubMed ID: 16463412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis.
    van Gaalen FA; van Aken J; Huizinga TW; Schreuder GM; Breedveld FC; Zanelli E; van Venrooij WJ; Verweij CL; Toes RE; de Vries RR
    Arthritis Rheum; 2004 Jul; 50(7):2113-21. PubMed ID: 15248208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope.
    Lakos G; Soós L; Fekete A; Szabó Z; Zeher M; Horváth IF; Dankó K; Kapitány A; Gyetvai A; Szegedi G; Szekanecz Z
    Clin Exp Rheumatol; 2008; 26(2):253-60. PubMed ID: 18565246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study.
    Gilliam BE; Chauhan AK; Low JM; Moore TL
    Clin Exp Rheumatol; 2008; 26(3):492-7. PubMed ID: 18578976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.
    Vallbracht I; Rieber J; Oppermann M; Förger F; Siebert U; Helmke K
    Ann Rheum Dis; 2004 Sep; 63(9):1079-84. PubMed ID: 15308516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.